Close Menu

NEW YORK (GenomeWeb) – NanoString Technologies announced today that health insurer Aetna has added the Prosigna breast cancer test to its Tumor Markers Clinical Policy Bulletin, opening the door for test coverage.

The decision provides access to Prosigna for Aetna's 19 million insurance plan members. Prosigna is an in vitro diagnostic test that uses the PAM50 gene expression signature to assess prognosis and risk of disease recurrence for patients with specific types of hormone receptor-positive breast cancer.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.

Michael Caputo, the top Department of Health and Human Service spokesperson, is taking a leave of absence, CNN says.

CNBC reports that the CDC Director says a SARS-CoV-2 vaccine isn't likely to be generally available until the third quarter of 2021, timing President Donald Trump disputes.

In Nature this week: MassIVE.quant resource houses mass spectrometry-based proteomic data, influence of Viking genetics on European populations, and more.